ICD-10-CM Code C90.11

Plasma cell leukemia in remission

Version 2021 Billable Code

Valid for Submission

C90.11 is a billable code used to specify a medical diagnosis of plasma cell leukemia in remission. The code is valid for the fiscal year 2021 for the submission of HIPAA-covered transactions. The ICD-10-CM code C90.11 might also be used to specify conditions or terms like immunoproliferative neoplasm in remission or multiple myeloma in remission or plasma cell leukemia or plasma cell leukemia in remission.

ICD-10:C90.11
Short Description:Plasma cell leukemia in remission
Long Description:Plasma cell leukemia in remission

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Immunoproliferative neoplasm in remission
  • Multiple myeloma in remission
  • Plasma cell leukemia
  • Plasma cell leukemia in remission

Diagnostic Related Groups

The ICD-10 code C90.11 is grouped in the following groups for version MS-DRG V38.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2021.

  • 820 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC
  • 821 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC
  • 822 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC

Convert C90.11 to ICD-9

  • 203.11 - Plsm cell leuk w rmson

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
      • Multiple myeloma and malignant plasma cell neoplasms (C90)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021

Information for Patients


Multiple Myeloma

Also called: Plasma-cell myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.

No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include

  • Bone pain, often in the back or ribs
  • Broken bones
  • Weakness or fatigue
  • Weight loss
  • Frequent infections and fevers
  • Feeling very thirsty
  • Frequent urination

Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute

  • Bence-Jones protein - quantitative (Medical Encyclopedia)
  • Bone marrow transplant (Medical Encyclopedia)
  • Multiple myeloma (Medical Encyclopedia)
  • Protein electrophoresis - serum (Medical Encyclopedia)
  • Serum globulin electrophoresis (Medical Encyclopedia)

[Learn More]